279 related articles for article (PubMed ID: 24951454)
1. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
[TBL] [Abstract][Full Text] [Related]
2. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
4. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
[TBL] [Abstract][Full Text] [Related]
5. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.
Dickson PI; Hanson S; McEntee MF; Vite CH; Vogler CA; Mlikotic A; Chen AH; Ponder KP; Haskins ME; Tippin BL; Le SQ; Passage MB; Guerra C; Dierenfeld A; Jens J; Snella E; Kan SH; Ellinwood NM
Mol Genet Metab; 2010; 101(2-3):115-22. PubMed ID: 20655780
[TBL] [Abstract][Full Text] [Related]
6. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
[TBL] [Abstract][Full Text] [Related]
8. Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
Chiaro JA; O'Donnell P; Shore EM; Malhotra NR; Ponder KP; Haskins ME; Smith LJ
J Bone Miner Res; 2014 Dec; 29(12):2610-7. PubMed ID: 24898323
[TBL] [Abstract][Full Text] [Related]
9. Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.
Auclair D; Hopwood JJ; Lemontt JF; Chen L; Byers S
Mol Genet Metab; 2007 Aug; 91(4):352-61. PubMed ID: 17544310
[TBL] [Abstract][Full Text] [Related]
10. Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice.
Bidone J; Schuh RS; Farinon M; Poletto É; Pasqualim G; de Oliveira PG; Fraga M; Xavier RM; Baldo G; Teixeira HF; Matte U
Int J Pharm; 2018 Sep; 548(1):151-158. PubMed ID: 29940298
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
12. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
[TBL] [Abstract][Full Text] [Related]
14. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
Auclair D; Hein LK; Hopwood JJ; Byers S
Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs.
Passage MB; Krieger AW; Peinovich MC; Lester T; Le SQ; Dickson PI; Kakkis ED
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1(Suppl 1):S253-8. PubMed ID: 19562502
[TBL] [Abstract][Full Text] [Related]
16. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
[TBL] [Abstract][Full Text] [Related]
17. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
[TBL] [Abstract][Full Text] [Related]
18. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
[TBL] [Abstract][Full Text] [Related]
19. Determination of synovial fluid and serum concentrations, and morphologic effects of intraarticular ceftiofur sodium in horses.
Mills ML; Rush BR; St Jean G; Gaughan EM; Mosier D; Gibson E; Freeman L
Vet Surg; 2000; 29(5):398-406. PubMed ID: 10999453
[TBL] [Abstract][Full Text] [Related]
20. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
